Drug Profile

LQT 1213

Alternative Names: Islasertib - Thryv Therapeutics; LQT-1213

Latest Information Update: 21 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Thryv Therapeutics
Class Antiarrhythmics; Cardiovascular therapies; Small molecules
Mechanism of Action Serum-glucocorticoid regulated kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Long QT syndrome
New Molecular Entity Yes

Highest Development Phases

Phase I/II Long QT syndrome

Most Recent Events

13 May 2025 Efficacy and adverse events data from phase I/II trial for Long QT syndrome released by Thryv Therapeutics
05 Mar 2025 Thryv Therapeutics plans a phase II trial for Long QT syndrome Type 1 in 2025 (Thryv Therapeutics pipeline, March 2025)
15 Oct 2024 Efficacy and adverse events data from phase I/II trial for Long QT syndrome released by Thryv Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com